Profile 420 Lexington Avenue Suite 2012 New York, NY 10170 United States 212-297-0020 http://www.synergypharma.com Sector: Healthcare Industry: Drug Manufacturers - Other Full Time Employees: 61 Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. The company has a research collaboration with BIND Therapeutics, Inc. to develop ACCURINS for treatment of a range of cells with novel therapeutic payloads. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. More about Synergy Pharmaceuticals Inc.>>> http://finance.yahoo.com/quote/SGYP/profile Statistic http://finance.yahoo.com/quote/SGYP/key-statistics?p=SGYP Mixing news http://finance.yahoo.com/quote/SGYP/?p=SGYP Holders http://finance.yahoo.com/quote/SGYP/holders?p=SGYP
Synergy Pharmaceuticals Inc. (SGYP) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 5.70+0.33 (+6.15%) At close: March 3 4:00PM EST Day's Range 5.41 - 5.71 52 Week Range 2.50 - 7.15 Volume 4,390,029 Avg. Volume 6,955,331 Resist. 6.43 then 7.15 Support: 5.26 Jan-20-17 Reiterated Rodman & Renshaw Buy $17 → $18 Jan-05-17 Initiated Oppenheimer Outperform
This share looks to be something of a trader’s paradise with some relatively volatile movements while maintaining an uptrend since November last year. The $5.70 mark would seem to be the next support level which will either see the share price rebound higher or experience a sell-off taking the shares lower.
If the $5.70 support fails the next support level is around $5.00 when the 200 day moving average kicks in.
Owch! This one has taken a bath - think as well as recommending stock charts to look at we need to note when the trends change.
